This inventor holds 2 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Exosomics S.p.a., Medica Corporation. Active years: 2024-2025.
Company Filing History:
Years Active: 2024-2025
Title: Davide Zocco: Innovator in Exosome Research
Introduction
Davide Zocco is a prominent inventor based in Siena, Italy. He has made significant contributions to the field of exosome research, particularly in methods related to cancer diagnostics and treatment. With a total of 2 patents, Zocco's work is paving the way for advancements in medical technology.
Latest Patents
Zocco's latest patents include innovative methods and kits for capturing CA-IX positive exosomes. These methods involve isolating tumor-derived exosomes through immunocapture with an anti CA-IX antibody. This process allows for the quantification of tumor-related nucleic acid sequences from the isolated exosomes, aiding in the determination of the presence of a tumor in a subject. Additionally, he has developed a method utilizing hollow fibers to obtain blood or blood derivatives that are impoverished from blood cells and platelets, specifically targeting extracellular vesicles such as exosomes and exomers. This method employs hollow fibers with a porosity above 20 nm, particularly polyethersulfone hollow fibers, to enhance the efficiency of sample processing.
Career Highlights
Throughout his career, Davide Zocco has worked with notable companies such as Medica S.p.a. and Exosomics S.p.a. His expertise in exosome research has positioned him as a key figure in the development of diagnostic tools and therapeutic strategies in oncology.
Collaborations
Zocco has collaborated with esteemed colleagues, including Antonio Chiesi and Natasa Zarovni. These partnerships have further enriched his research and contributed to the advancement of innovative solutions in the medical field.
Conclusion
Davide Zocco's contributions to exosome research and his innovative patents highlight his role as a leading inventor in the medical technology sector. His work continues to influence the landscape of cancer diagnostics and treatment.